These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24328536)

  • 1. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
    Metwally MA; Frederiksen KD; Overgaard J
    Acta Oncol; 2014 May; 53(5):654-61. PubMed ID: 24328536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
    Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
    Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of head and neck cancer with CHART and nimorazole: phase II study.
    Henk JM; Bishop K; Shepherd SF
    Radiother Oncol; 2003 Jan; 66(1):65-70. PubMed ID: 12559522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial.
    Hassan Metwally MA; Jansen JA; Overgaard J
    Clin Oncol (R Coll Radiol); 2015 Mar; 27(3):168-75. PubMed ID: 25530485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer.
    Cottrill CP; Bishop K; Walton MI; Henk JM
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):807-10. PubMed ID: 9845101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
    Overgaard J; Hoff CM; Hansen HS; Specht L; Overgaard M; Lassen P; Andersen E; Johansen J; Andersen LJ; Evensen JF; Alsner J; Grau C
    Radiother Oncol; 2018 Apr; 127(1):12-19. PubMed ID: 29523409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.
    Overgaard J; Hansen HS; Overgaard M; Bastholt L; Berthelsen A; Specht L; Lindeløv B; Jørgensen K
    Radiother Oncol; 1998 Feb; 46(2):135-46. PubMed ID: 9510041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer.
    Thomson D; Yang H; Baines H; Miles E; Bolton S; West C; Slevin N
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):344-7. PubMed ID: 24685344
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD).
    Thomson DJ; Slevin NJ; Baines H; Betts G; Bolton S; Evans M; Garcez K; Irlam J; Lee L; Melillo N; Mistry H; More E; Nutting C; Price JM; Schipani S; Sen M; Yang H; West CM;
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):771-782. PubMed ID: 38072326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
    Corvò R
    Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy quality assurance of the IAEA-HypoX trial of the accelerated radiotherapy in the treatment of head and neck squamous cell carcinoma with or without the hypoxic radiosensitizer nimorazole.
    Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Overgaard J; Grau C
    Acta Oncol; 2015; 54(9):1673-7. PubMed ID: 26397148
    [No Abstract]   [Full Text] [Related]  

  • 14. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.
    Overgaard J; Hansen HS; Specht L; Overgaard M; Grau C; Andersen E; Bentzen J; Bastholt L; Hansen O; Johansen J; Andersen L; Evensen JF
    Lancet; 2003 Sep; 362(9388):933-40. PubMed ID: 14511925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.
    Toustrup K; Sørensen BS; Lassen P; Wiuf C; Alsner J; Overgaard J;
    Radiother Oncol; 2012 Jan; 102(1):122-9. PubMed ID: 21996521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity.
    Saksø M; Jensen K; Andersen M; Hansen CR; Eriksen JG; Overgaard J
    Radiother Oncol; 2020 Jul; 148():65-72. PubMed ID: 32335364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.
    Eriksen JG; Overgaard J;
    Radiother Oncol; 2007 Jun; 83(3):383-8. PubMed ID: 17543403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts.
    Koi L; Bitto V; Weise C; Möbius L; Linge A; Löck S; Yaromina A; Besso MJ; Valentini C; Pfeifer M; Overgaard J; Zips D; Kurth I; Krause M; Baumann M
    J Transl Med; 2023 Aug; 21(1):576. PubMed ID: 37633930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
    Masunaga S; Uto Y; Nagasawa H; Hori H; Nagata K; Suzuki M; Kinashi Y; Ono K
    Anticancer Res; 2006; 26(2A):1261-70. PubMed ID: 16619533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.